by Chris Dokomajilar | May 23, 2023 | Analysis, M&A
Biopharma M&A started to in the first quarter of 2023 after a slow 2022. Major deals included Moderna’s acquisition of OriCiro Genomics for $85 million, expanding Moderna’s manufacturing capabilities for mRNA vaccines. Pfizer’s blockbuster $43...
by Chris Dokomajilar | Apr 20, 2023 | Analysis, M&A
First quarter 2023 deal activity followed very similar trends from 2022 with continued declines in venture investment and dealmaking. One area that did pick up slightly in the total Q1 numbers was biopharma M&A, mainly driven by early January acquisition activity...
by Chris Dokomajilar | Apr 19, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D Partnerships, M&A, Ventures, and IPOs by TA – Neurology The biotech industry is facing a critical moment as it enters 2023. The previous year was challenging for the sector, as initial public offerings decreased, and a biotech stock index declined by...
by Chris Dokomajilar | Apr 3, 2023 | Analysis, Funding, M&A, Partnership Deals
Deal Flow in 2022 Returned to pre-2019 Levels Lower Deal Dollars Across All Healthcare and Life Sciences Licensing Terms are Shifting to More in Milestones Large Cap Biopharma In-Licensing and Buying in 2022 Big...
by Chris Dokomajilar | Mar 16, 2023 | Analysis, Funding, M&A, Partnership Deals
R&D Partnerships, M&A, Ventures, & IPOs in T.A. – Cancer The pharmaceutical industry continues to place significant emphasis on cancer treatment. A report by the International Agency for Cancer Research suggests that the number of deaths resulting from...
by Chris Dokomajilar | Mar 11, 2023 | Analysis, M&A
M&A – Medtech Medical technology, or MedTech, is a multidisciplinary field that combines technology and medical interventions. It encompasses various technologies, devices, services, products, and solutions that employ medical technology to improve patient care...
